BUSINESS SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2012

Concentration Risk [Line Items]

Gross sales to three largest pharmaceutical wholesalers in the U.S. [Table Text Block]

	2012	2011	2010
McKesson Corporation	23%	26%	24%
Cardinal Health, Inc.	19%	21%	21%
AmerisourceBergen Corporation	14%	16%	16%

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	Net Sales						Property, Plant and Equipment
Dollars in Millions	2012		2011		2010		2012		2011
United States(a)	$	10,384	$	14,039	$	12,800	$	4,464	$	3,538
Europe(b)		3,706		3,879		3,672		740		886
Rest of the World(c)		3,204		3,237		2,900		129		97
Other(d)		327		89		112		-		-
Total	$	17,621	$	21,244	$	19,484	$	5,333	$	4,521

Net sales of key products [Text Block]

		Year Ended December 31,
Dollars in Millions		2012		2011		2010
Plavix* (clopidogrel bisulfate)		$	2,547	$	7,087	$	6,666
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)			503		952		1,176
Eliquis (apixaban)			2		-		-
Abilify* (aripiprazole)			2,827		2,758		2,565
Reyataz (atazanavir sulfate)			1,521		1,569		1,479
Sustiva (efavirenz) Franchise			1,527		1,485		1,368
Baraclude (entecavir)			1,388		1,196		931
Erbitux* (cetuximab)			702		691		662
Sprycel (dasatinib)			1,019		803		576
Yervoy (ipilimumab)			706		360		-
Orencia (abatacept)			1,176		917		733
Nulojix (belatacept)			11		3		-
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)			709		473		158
Byetta* (exenatide)			149		N/A		N/A
Bydureon*(exenatide extended-release for injectable suspension)			78		N/A		N/A
Mature Products and All Other			2,756		2,950		3,170
	Net Sales	$	17,621	$	21,244	$	19,484